This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Meg Brousseau, Ph.D.
Executive Director, Cardiovascular & Metabolic Diseases at Novartis


Meg has been a member of the Cardiovascular and Metabolic (CVM) Diseases Area at Novartis for over 18 years. Her work is focused on the identification of novel therapies for dyslipidemias and atherosclerotic cardiovascular disease (ASCVD). She is a member of CVM’s Leadership Team and oversees CVM’s effort to develop oligonucleotide therapies toward reducing ASCVD risk at scale. Prior to joining Novartis, Meg was an Assistant Professor of Medicine and Nutrition Science and Policy at Tufts University. Her academic research focused on genetic causes of lipoprotein disorders and defining the impact of dietary and therapeutic interventions on lipoprotein kinetics. Meg received her Ph.D. from Tufts University and completed a post-doctoral fellowship at the National Institutes of Health (Molecular Disease Branch/National Heart, Lung and Blood Institute).

Agenda Sessions

  • Tackling ASCVD at Scale Via a Suite of Long-acting Oligonucleotide Therapies